FTC Solar (NASDAQ:FTCI) reported quarterly adjusted losses of $(0.11) per share which met the analyst consensus estimate. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $26.20 million which missed the analyst consensus estimate of $30.38 million by 13.76 percent. This is a 74.24 percent decrease over sales of $101.72 million the same period last year.
Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced
